Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study
Author:
De Vito Andrea1ORCID, Moi Giulia1, Saderi Laura2ORCID, Puci Mariangela V.2ORCID, Colpani Agnese1ORCID, Firino Laura3, Puggioni Anna3, Uzzau Sergio3ORCID, Babudieri Sergio1ORCID, Sotgiu Giovanni2ORCID, Madeddu Giordano1ORCID
Affiliation:
1. Unit of Infectious Disease, Department of Medicine, Surgery, and Pharmacy, University of Sassari, 07100 Sassari, Italy 2. Clinical Epidemiology and Medical Statistics Unit, Department of Medicine, Surgery and Pharmacy, University of Sassari, 07100 Sassari, Italy 3. Division of Microbiology and Virology, Department of Biomedical Sciences, University of Sassari, 07100 Sassari, Italy
Abstract
Clinical trials demonstrated the role of vaccines and antiviral treatments against SARS-CoV-2 in reducing the likelihood of disease progression and death. However, there are limited data available regarding the time to negativity of people who received these treatments. Further, several comorbidities and risk factors might affect the impact of vaccines and antiviral treatments. To this end, we aimed to evaluate and disentangle the impact of anti-SARS-CoV-2 treatments and that of underlying clinical factors associated with a shortened length of SARS-CoV-2 infection. Hence, we recorded the timeframe of positive nasopharyngeal swab in people infected while being hospitalized for reasons other than SARS-CoV-2 infection. All patients who died or were discharged with a positive swab were excluded from the study. A total of 175 patients were included in this study. Clinical conditions encompass malignancies, immunological disorders, cardiovascular, metabolic, neurodegenerative, and chronic kidney disease. Most of the participants (91.4%) were vaccinated before admission to the hospital, and 65.1% received antiviral treatment within three days after the symptom’s onset. Unvaccinated patients had a longer median time to negativity than people who received at least two doses of vaccine (18 vs. 10 days). Concerning the clinical conditions of all patients, multivariate analysis highlighted a lower probability of 14-day conversion of antigenic test positivity in patients with hematological malignancy, including those vaccinated and those exposed to antiviral therapies. In conclusion, our data showed that prompt administration of antiviral treatments accelerates the clearance of SARS-CoV-2. Further, in the elderly patients under study, previous vaccination and antiviral treatment synergize to reduce time to negativity. This translates into a shorter hospitalization time and a lower risk of transmission through patients and connected healthcare workers in a hospital ward setting, with considerable improvement in cost-effective care management.
Subject
Virology,Infectious Diseases
Reference31 articles.
1. Coronavirus Disease 2019—Historical Context, Virology, Pathogenesis, Immunotherapy, and Vaccine Development;Ezzikouri;Hum. Vaccines Immunother.,2020 2. De Vito, A., Fiore, V., Princic, E., Geremia, N., Panu Napodano, C.M., Muredda, A.A., Maida, I., Madeddu, G., and Babudieri, S. (2021). Predictors of Infection, Symptoms Development, and Mortality in People with SARS-CoV-2 Living in Retirement Nursing Homes. PLoS ONE, 16. 3. A Case of Vasculitis-Like Skin Eruption Associated With COVID-19;Geremia;Infect. Dis. Clin. Pract.,2020 4. Grant, M.C., Geoghegan, L., Arbyn, M., Mohammed, Z., McGuinness, L., Clarke, E.L., and Wade, R.G. (2020). The Prevalence of Symptoms in 24,410 Adults Infected by the Novel Coronavirus (SARS-CoV-2; COVID-19): A Systematic Review and Meta-Analysis of 148 Studies from 9 Countries. PLoS ONE, 15. 5. Systemic Inflammatory Markers and Psychophysical Olfactory Scores in Coronavirus Disease 2019 Patients: Is There Any Correlation?;Vaira;J. Laryngol. Otol.,2021
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|